| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 |
| Total Income - EUR | 17.240 | 9.414 | 733 | 4 | 1.418 | 0 | 0 | - | 136 | 58 |
| Total Expenses - EUR | 22.960 | 12.211 | 15.307 | 898 | 13.396 | 428 | 23.443 | - | 3.741 | 397 |
| Gross Profit/Loss - EUR | -5.720 | -2.797 | -14.575 | -894 | -11.978 | -428 | -23.443 | - | -3.605 | -339 |
| Net Profit/Loss - EUR | -5.720 | -2.797 | -14.575 | -894 | -11.978 | -428 | -23.443 | - | -3.605 | -339 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 |
Check the financial reports for the company - Dopharma Invest S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 428.229 | 423.862 | 416.690 | 409.043 | 401.121 | 393.517 | 384.790 | - | 384.814 | 382.663 |
| Current Assets | 21.100 | 20.325 | 20.335 | 19.587 | 17.795 | 17.030 | 16.108 | - | 16.815 | 16.324 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 |
| Receivables | 3.636 | 3.600 | 3.540 | 3.476 | 3.410 | 3.346 | 3.274 | - | 3.278 | 3.261 |
| Cash | 17.464 | 16.725 | 16.795 | 16.111 | 14.386 | 13.684 | 12.835 | - | 13.536 | 13.063 |
| Shareholders Funds | -137.012 | -138.411 | -150.644 | -148.773 | -157.870 | -155.305 | -175.304 | - | -177.738 | -177.083 |
| Social Capital | 7.147 | 7.074 | 6.955 | 6.827 | 6.695 | 6.568 | 6.422 | - | 6.423 | 6.387 |
| Debts | 586.341 | 582.598 | 587.668 | 577.402 | 576.787 | 565.852 | 576.202 | - | 579.366 | 576.070 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6810 - 6810" | |||||||||
| CAEN Financial Year |
6810
|
|||||||||
Comments - Dopharma Invest S.r.l.